Mitsubishi Tanabe Pharma Corporation
Information Meeting

Becoming a “Company that Can
Continue to Provide New Value”
February 21, 2013
Michihiro Tsuchiya

President andRepresentative Director

Today’s Topics
Medium-Term Management Plan 11-15: Results in the First Two Years
Initiatives Targeting Sustained Growth toward 2015:
Issues for the Next Three Years Growth strategies for Remicade and Simponi
 Growth of Gilenya/Imusera
 Taking on challenges in the diabetes area (Tenelia, TA-7284)
 Strategy for nurturing new products / priority products (Lexapro, Talion, Telavic)

 Promising pipeline (MT-1303, MP-214, MT-4666, MT-3995, MT-9938)
Other Initiatives
 Operational and Structural Reforms
 Contributing to KAITEKI Society by orchestrating1Medium-Term Management Plan 11-15:
Results in the First Two Years

Page.2

2

Operating Environment
in the Pharmaceutical Industry
Maturation of Medicine
 Increase in patients by the aging society Advances in medicine

Control of health care expenditures
because of growth in health carespending• Promotion of use of generics• Revisions of NHI drug price and NHI
drug system

Maturation of pharmaceutical market
 Intensifying competition among companies
Decline in earning power Increase in log-listed drugs
 Increase in R&D expenses due to the decline
in development success rate
• Expansion of operational scale ofcompanies by M&A and cooperation• Selection and concentration on
business activities
3Medium-Term Management Plan 11-15
Success in These Two Years
Success to Date
Bolstering Our
Ability to
Discover New
Drugs

 Launched 6 new drugs (Lexapro, Simponi, Telavic, Imusera, Tenelia, Tetrabik）
 Taking on challenges in diabetes field (Launch of Tenelia, strategic joint sales
agreement with Daiichi Sankyo)
 Steadily implementing LCM (Remicade, Maintate, others)

Advancing
Domestic
Operations,Centered on
New Drugs

 Progress in domestic and overseas development pipelines
P3: TA-7284 (Japan), P2b/3: MP-214 (Japan)
P2: MT-4666 (Japan), MT-9938 (US) , MT-3995 (Europe)
In preparation for P2: MT-1303 (Europe)

Building aFoundation
for the
Expansion ofOverseas
Operations
Accelerating
Operationaland Structural
Reforms Progress in development by out-licensing partners
Gilenya: Grow to blockbuster
TA-7284: NDAs filed in Europe and US, approval recommended in US
TA-1790: NDAs filed in Europe and US, approval received in US
 Progress with in-house development
Argatroban: Launched in increasing number of markets (11 countries)
MCI-196: Approved in Europe; Talion: Launched in China, Indonesia
 Integrated plasma fractionation operations with the Japanese Red Cross Society Transferred fine chemical operations
 Outsourced logistics operations

4

FY2015 Numerical Targets
FY2011 actual

FY2012 forecast

FY2015 objectives

Sales¥ 407.1 billion¥ 425.0 billion¥ 500.0 billion

Operating income¥ 69.0 billion¥ 70.0 billion¥ 100.0 billion

7.0%

9.6%

15% +

Overseas sales ratio
JPY b

JPY b

500
400

250

Sales

150 R&D expenses

Sales 300
200

200

R&D expenses
Operating
Income1000Operating income

100
50
0

FY2008 FY2009 FY2010 FY2011 FY2012 FY2013 FY2014 FY2015(forecast)5

Initiatives Targeting Sustained Growth toward 2015:
Issues for the Next Three Years

Page.666

For the patients –the improvements of healthand treatment satisfaction-

For the patients
Patients

Medicalpersonnel

MTPC

Postmarketingdevelopment

Usage Experience
Evidence

Drug
Development
Drug
Discovery

Customer Needs
 Best targets and usage※
 New indications(additional
indications) New formulation (additional
formulations)※Maximize effects, minimize side effects

7

Future Marketing Strategy that
Reflects System Reforms

Early maximization of product value[Targeting First in category / Only one in category] Active cooperative initiatives:
Maximizing sales capabilities Co-marketing Co-promotion
 Reinforcing the partnershipwith wholesalers Advancing LCM:
 Evidence Additional
indications/formulations
 Information provision:
Maximizing product value
 T-Shaped Marketing system Group cooperative initiatives andstrategic alliances

Expected to generate earnings
as foundation business Utilizing multiple channels*Mature products: Long-listed drug except for priority products8Growth strategies for Remicade and Simponi

Page.999

Remicade & Simponi: Advantages■Advantages of the one-company, two-drug approach• Can provide large quantity of information accumulated• Can propose drugs to meet patient needs and lifestyles (intravenous injection,
subcutaneous injection)• Can be the first to identify patients for whom one of the drugs was not effective.

■Advantages shared by both drugs• Both target TNF• Both can be tightly controlled (setting dosage to obtain maximum effect)(possible to increase dosage)

Remicade：Rapid
Remission
Simponi：Simple
Sustain10

Remicade & Simponi:
Meeting the Next Treatment Needs in RA
Drug free after maintain of remission

Drug free
Functional
remission

Control of progression of joint destruction

Structural remission
Prompt effects

Clinical remission

Treatment targets

Benefit of tight control

Pain relief and symptom reduction
year

1970

1980

1990

Treatment

Anti-rheumatoid drugs

2003

2009

Remicade RA approval
MTX
Biologics

2010

2011

Simponi launched11Remicade & Simponi:¥ 100 billion of Sales in FY2013
150

JPY b

Remicade
Simponi

Shorter
infusiontime

2002: Launch for CD
2003: Additional indication of RA
100

RA: dose
escalation AS, UC
Psoriasis

50

Under development
Pediatric UC, pediatric CD,
refractory Kawasaki disease
Bechet’s disease withspecial lesions¥ 100
billionCD: dose
escalationCD
maintenanceBechet’s disease

FY2006

FY2007

FY2008FY2009FY2010FY2011FY2012FY2013

FY2014FY2015

CD: Crohn’s disease, RA: rheumatoid arthritis, AS: ankylosing spondylitis, UC: ulcerative colitis

12Growth of Gilenya/Imusera

Page.1313
13

Gilenya:Becoming a Blockbuster in 2 years after launch Novartis 2012 global sales: about $1.2 billion
 Approved in more than 65 countries, used in the treatment of more than 53,000
patients after marketing(USD m)
400

US

350

Global Sales(JPY b)4.5

Other than US

4Royalty Income

3.5

300

3

250

2.5

200

2

150

1.5

100

1

50

0.5

0

0

Q1

Q2

Q3
2011

Q4

Q1

Q2

Q3

2012

Q4
(Oct.-Dec.)

Q1

Q2

Q3

FY2011

Q4

Q1

Q2

Q3

(Oct.-Dec.)

Q4

FY2012

14

Taking on Challenges in the Diabetes Area
(Tenelia, TA-7284)）

Page.1515
15

Schedule of MTPC’s Diabetic Drugs
in Japan
2012

2013

2014

2015

Tenelia (DPP-4 inhibitor)
Addition of
combination

Long-termprescription

LaunchApproval

TA-7284/Canagliflozin (SGLT2 inhibitor)
Long-termprescription

LaunchApproval

Filed

Filed

Approval

US, Europe(for ref.)16

Tenelia: Priority Issues
Priority Issues

Measures

Shortterm
Short to long term

Promote rapid spread of
product profile Strengthen cooperation and activities among 4,000
MRs Emergence of unmet needs in diabetes treatment

Maximize product value

 Establish evidence Special post-marketing surveillance in 10,000
patients (RUBY trials)
 Anti-arteriosclerosis (endothelial cell function),others Meticulous preparations for change in usage, longterm administration

Promote spread of MTPC brand Advance patient support program Strengthen system for support of diabetes research Deepen T-Shaped system

Tenelia & TA-7284

Top tier presence in domestic market (diabetes field)
17

TA-7284 (SGLT2 inhibitor): Distinctive Features
Mechanism ofactionSGLT2 inhibitor

Indication

Type2 diabetes mellitus

Development
stage

Japan: Phase 3 (planning 1st half of FY2013)
US, Europe: Filed (by Janssen Pharmaceuticals) Abundant clinical data from Japan andoverseas (more than 12,000)

Distinctive
features Efficacious without regard to insulin status
 Low risk of hypoglycemia
 Weight reduction effect18

Change of weight from Baseline (%)

TA-7284(SGLT2 inhibitor):
Body Weight Reduction
0.0

W0

W4

W8

W12

W12LOCF P2 data, Japan
Mean %change frombaseline (±SE)

-1.0
-2.0
-3.0

PBO
50mg
100mg
200mg
300mg

-4.0
-5.0
PBO

50mg

100mg

200mg

300mg

n

75

82

74

76

75

BW at BL (kg)72.56
± 15.36

65.77± 13.56

68.61± 14.86

68.97± 14.5071.30± 12.19

Inagaki N. JDI 2012;3 (suppl1): 226

19

Advantage in Diabetic Area
■Major marketing authorization holders

DPP-4 inhibitor( ): Co-marketing or co-promotion

SGLT2 inhibitor

MSD, Ono

Astellas

MTPC(Sanofi, Kowa)

Boehringer Ingelheim

Taisho Toyama

Novartis Pharma

Chugai(Daiichi Sankyo)

TakedaSanwa(Lily)(Kowa)

Kyowa Hakko Kirin(Otsuka)(Novartis Pharma)

BMS
(AZ)

MTPC and Boehringer Ingelheim
are the originators having both drugs

20

Ideal Diabetic Treatment brought about by
Two Mechanisms of Action
Gentle treatment for pancreatic
β cells
Physiological insulin secretion by incretin

Pancreatic α
cells: Inhibitionof glucagon

Pancreatic β
cells: insulin
secretion

Reduction of CV risks by TENELIA® andcanagliflozin
Requirements to inhibit CV events

1. Adequate control of blood glucose
2. No hypoglycemia
3. No body weight gain

DPP-4 inhibitor
Glucose lowering
mediated by
Insulin

SGLT2 inhibitor
Reduction of
glucotoxicity byinhibition of
glucosereabsorption

4. Influence on blood pressure

TENELIA®

TA-7284

Improvement of
postprandial hyperglycemia

Improvement of fasting
hyperglycemia

Fewer hypoglycemia bymonotherapy

Fewer hypoglycemia bymonotherapy

No body weight increase

Body weight loss

No influence on blood pressure

Blood pressure decrease21

Medium- to Long-term Expansion
in Diabetic Area

22

Strategy for Nurturing New Products /Priority Products (Lexapro, Talion, Telavic)

Page.23

23
23

Lexapro: Global Evaluation
No.1 in MANGA study, famous for meta-analysis of antidepressantsEfficacy and Tolerability of antidepressants

MANGA Study: Meta-analysis of new generation antidepressants (Cipriani A. et al., Lancet 2009; 373, 746-758)
1.2

Escitalopram

Bupropion

1.1

Citalipram

Sertraline

Tolerability (odds ration)

Fruoxetine
1.0

Milnacipran

0.9

Paroxetine

Duloxetine

Mirtazapine
Venlafaxine

Fluvoxamine

0.8

Reboxetine
0.7

0.6
0.60

Fruoxetine isused as astandard.
0.70

0.80

0.90

1.00

1.10

Efficacy (odds ratio)

1.20

1.30

1.40

24

Lexapro: Priority Issues
Priority issues

Measures Strengthening of the marketing information
provision system(single visit ⇒ multi visits）
Short-term

Penetration of the
product concept

MTPC

MTPC

Yoshitomi
MochidaMochidaYoshitomiMed.- tolong-term

Maximization of the  Evidence in Japanproduct value Additional indication: Social anxiety disorder

Toward No.1 share in antidepressants25

Talion: Current Status
Market size and sharetrend of Talion(%)
20

Talion share

Market size

Market has grown to ¥200 billion
per year by increasing hay fever
patients.
JPY b

200
2000

00

FY07
FY10 FY11
FY09 10年
FY12
07年 FY08
08年 09年
11年 12年
度
度
度
度
度
度

Allegra0

Allelock

50
500

Claritin5

Ebastel100
1000

Zyrtec10

A spate of patent off;
In FY2012, GEs of Allegra andAllelock are launched.
Alesion

1500
150

Products.

15

Talion is expanding its market shareyear by year.

GE 2002 2007 2008 2011 2012 2013
launch Jul. Jul. Jul. Nov. Dec. Jan.
26

Talion: Priority Issues
Priority Issues
Increasepromotional
impactMeasures Continually provide evidence from Japanese patients and strengthen
product key message, as domestically produced antihistamine.
2010
ACROSS2007
ACTION

Develop newmarketCapture share in
existing market

2013
UPDATE2011
ACTIONⅡ

2015
Proactive
therapy
2012
ACTIONⅢ

 Preparations to obtain additional indication in pediatric field Establish product position through evidence from Japanese patientsand encourage switch to Talion from long-term listed products (1stgeneration products, etc.).

Develop to sales of ¥30 billion/year27

Telavic: Current Status■Efficacy
100

(%)

80

SVR
94.9% 96.5%

93.5% 92.4%

N=223 N=4,808

N=222 N=3,515

N=201

4wks dosing

12wks dosing

24wks dosing

85.1% 88.9%

60
40
20
0

P3 in Japan

N=582

Post marketing surveillance (before Nov. 22, 2012)■Safety
Skin symptom (grade3)

10 (%)
8

9.0%

6
4

4.7%

2
0

N=267

N=6,467

Post marketing surveillance(before Nov. 22, 2012)
Note: 1,500 mg dosage cases are included in PMS
P3 in Japan28

Telavic:
Priority Issues and Measures
Priority Issues
All-patient Safetysurveillance confirmation/usage
underwayestablishment
Aftercompletion Foster spread of usage
methodof allpatient
surveillance Develop new market

Measures Early completion of all-patient surveillance by speedingup the information collection and analysis Rapidly expand number of institutions[gastroenterologists] (continued links with dermatology)
 Disseminate knowledge about usage methods throughDoctor to Doctor* communications
 Additional indications (genotype 2, etc.)* At presentations and other venues, havedoctors who are opinion leaders provide
information to other doctors who have notused it yet or are not well acquainted with it.

Strive to expand sales based on the established safety evidence after theapproval conditions are lifted29

Promising Pipeline(MT-1303, MP-214, MT-4666, MT-3995, MT-9938)

Page.30

30
30

Pipeline Status (Japan)
Red: progress after April 2011
Phase 1
■MT-3995
Hypertrophy■MT-1303
Multiple sclerosis

In-house Development■Cholebine
Hyperphosphatemia

Phase 2■MP-435
RA■MT-4666
Alzheimer’s disease■CholebineType 2 diabetes
mellitus

Filed

Phase 3■TA-7284

Type 2 diabetes
mellitus■RadicutPediatric allergic
rhinitis■Simponi■Maintate■Telavic

Chronic atrial fibrillation■Grtpa■Telavic

Chronic hepatitis C,
genotype2

Type2 diabetes mellitus,
additional combination■Remicade

Chronic hepatitis C■ Tenelia

Type2 diabetes
Acute ischemic
cerebrovascular disease, ■Tetrabik
up to 4.5h after the onset
Tetra vaccineof symptoms■Maintate■Tenelia/MP-513
Disease area■：Autoimmune disease■：Diabetes and kidneydisease■：CNS disease■：Other(After April 2011)

Helicobacter pylori
RA
eradication by concomitant ■Imusera
therapy for helicobacter
Multiple sclerosis
pylori gastritis

ALS■TalionApproved, Launch■Omeprazon■MP-214

Schizophrenia

As of Feb. 1, 2012

Refractory Kawasaki disease
Bechet’s disease with special lesions
Pediatric CD
Pediatric UC
Psoriasis: increased dose

Chronic heart failure■Novastan

Dialysis, PCI in HIT■Azanin

Systemic vasculitis■Remicade

CD: dose escalation■Modiodale

Obstructive sleep apnea

Major
license-out■TA-7906
Atopic dermatitis

31

Pipeline Status (Overseas)
Red: progress after April 2011
Phase 1

Phase 2In-house Development■MT-1303 (Europe)■ MT-9938 (US)■MP-146(US, Europe)
Multiple sclerosis
Chronic kidney
Refractory pruritus■MP-513 (US)disease■MP-513 (Europe)
Type2 diabetes mellitus
Type2 diabetes mellitus■ MT-7716 (US)
Alcohol-use disorder■MP-124 (US, Canada)
Acute ischemic stroke■ MT-3995 (Europe)
Hypertension →P2 start in Diabetes nephropathy■ MP-157 (Europe)
Hypertention■ GB-1057 (US)Stabilizing agent

Majorlicense-out

Disease area■：Autoimmune disease■：Diabetes and kidneydisease■：CNS disease■：Other■TA-7284(US, Europe)
Obesity

Filed

Phase 3■MP-513(Korea)Type2 diabetes
mellitus

As of Feb. 1, 2012

Approved, Launch(After April 2011)■MP-424 (Taiwan)
Chronic hepatitis C■Talion (China, Indonesia)
Allergic disease■Simponi (Taiwan, Indonesia)
RA, ankylosing spondylitis■Livalo (Indonesia)
Primary hyperlipidemia ,mixed dyslipidemia■Livalo (Taiwan)
Primary hyperchoresteremia,
mixed dyslipidemia■Exembol (UK)HIT type II■BindRen (Europe)
Hyperphosphatemia■TA-7284(US, Europe)■TA-1790 (Korea, US)ED

Type2 diabetes
mellitus■TA-1790(Europe)ED

32

Nurturing of Three Disease Areas:

Autoimmune disease, Diabetes and Kidney Disease, CNS disease

Autoimmune
disease
Remicade
Simponi
ImuseraMT-1303

CNS disease
LexaproTA-7284
MT-3995
MT-9938

Diabetes andkidney disease
Tenelia
TanatrilKremezin
BindRen
MP-214
MT-4666
33

Nurturing of Autoimmune Disease AreaHigh

Treatment satisfaction(autoimmune disease)
Low

Anti human TNFα
antibody

Low molecularcompoundRemicade, iv

Imusera, po(LCM is underway, for pediatricuse, etc.)（LCM is underway, for CIDP）

Simponi, sc(LCM is underway)

MT-1303, po(Preparing for P2 in Europe)• Improvement oftreatment
and compliance• Improvement oftreatment• Oral drug

DMARDsMTXNSAIDsIFN
Glatiramer

RA, IBD, psoriasis

Multiple sclerosis
34

Nurturing of Autoimmune Disease Area
Expansion of indication based on Remicade experiences
Red:
Developments
are underway

Refractory
Kawasaki disease

Pediatric

Ulcerative colitis

Doseescalation

PsoriasisWithspeciallesions

Bechet’s disease

Ankylosing
spondylitis

RA
Pediatric

Other
autoimmune
diseaseUlcerative colitis *In preparation
RA

Crohn’s disease

Remicade

Simponi

Multiple sclerosis

Multiple sclerosis

ImuseraMT-1303*: developed by Janssen Pharmaceutical35

MT-1303 for Multiple Sclerosis
Mechanism ofactionS1P receptor functional antagonist

Indication

Multiple sclerosis and other autoimmune disease

Development
stage

Japan: Phase1
Europe: preparing for Phase2b
 Equivalent efficacy to FTY720 (Imusera)

Distinctive
features Circulatory system side effects have been eliminated,
and the high level of safety that is better than others Using FTY720 (Imusera) development know-how
 Are now considering development for indications
other than MS, using Remicade development knowhow
36

Nurturing of CNS Disease Area
Complement of three major disease in CNS

DepressantSchizophrenia

LexaproAlzheimer’s
disease37

Nurturing of CNS Disease Area

CNS disease area
Alzheimer’s
diseaseClinical symptom,
for example: problem
behavior

Cognition
disorderSchizophrenia
Negative symptom
Positive symptom

38
MT-4666(P2b in Japan)

MP-214(P2b/3 in Japan,
Korea and Taiwan)

38

MP-214 (cariprazin) for Schizophrenia
Mechanism ofactionD3/D2 receptor partial agonist

Indication

Schizophrenia

Development
stage

Japan, Korea, Taiwan: Phase2b/3

Originator

Gedeon-Richter (Hungary) Expected to show efficacy for both positive symptoms
and negative symptoms

Distinctive
features With limited side effects, it is expected to be suitable
for long-term use P3 results in Europe and the U.S. for schizophrenia
show results equivalent to or better than aripiprazole.
39MT-4666 for Alzheimer’s Disease
Mechanism ofactionα７nACh receptor agonist

Indication

Japan: Alzheimer’s disease

Development
stage

Japan: Phase2b

Originator

EnVivo (US)Distinctive
features In phase 2b trials overseas (conducted by EnVivo), it
had good results in improving cognitive function andclinical symptoms in Alzheimer’s（expected to be first inclass）.
 Expected to be used concomitantly with such drugs as
donepezil, rivastigmine, and galantamine40MT-4666, Treatment for Alzheimer’s disease
Glutamatergic neuron

Cholinergic neuron

Ca2+

Ca2+

α7

α7

Glu
Release

Glu

NMDA

ACh
Releaseα7nACh receptor agonist

AChMT-4666

AMPA

Activation of Glu signaling

ACh: acetylcholine
Glu: glutamic acid×

AChE inhibitor
Donepezil

Degradation

Ch

α7

M1

α4β2

Activation of ACh signaling

Activation of cognition function
41

Nurturing of Diabetes and Kidney Disease Area

Type 2 diabetes
mellitus
Tenelia
Type 2 diabetes
mellitus
TA-7284

Diabetic
nephropathy
MT-3995
Diabetic
nephropathy
Tanatril

Chronic kidney
failureKremezin
BindRen

Refractory
pruritus
MT-9938
42

Nurturing of Diabetes and Kidney Disease Area
Chronic kidney
failureKremezin

Diabetes nephropathy
MT-3995

Refractory
pruritus
MT-9938
Hyperphosphatemia
BindRen(Type1 diabetes mellitus) Diabetes nephropathy, Tanatril
Type2 diabetes mellitus, Tenelia

Type2 diabetes mellitus
TA-7284
Stage 1
General physicians

CKD severity
Nephrologists

Stage 5
Dialysis specialists

43MT-3995 for Diabetes Nephropathy
Mechanism ofactionSelective mineralocorticoid receptor antagonist

Indication

Diabetes nephropathy

Development
stage

Japan: Phase1
Europe: Phase2 (Feb. 2012) In pre-clinical trials, anti-albuminuria effects confirmed

Distinctive
features Has non-steroid structure, avoids sex hormone relatedside effects.
 As a new generation mineralocorticoid receptor
antagonist, phase 2 trials have begun for diabetic
nephropathy.

44

MT-9938 for Refractory Pruritus
Mechanism ofactionκ-opioid receptor agonist

Indication

Refractory pruritus (for hemodialysis patients)

Development
stage

US: Phase2b

Distinctive
features Fewer physical and mental addiction, compared withmorphine Action on CNS and inhibition of pruritus independent
from histamine, liver and kidney failure Expected to be first in class45

Other Initiatives:
Operational and Structural Reforms

Page.46

46
46

Strengthening and Expanding
the Vaccine Business
Vaccine Business Policy
In addition to the discovery and provision of drugs to treat diseases, by
supplying vaccines we will also contribute to improving the QOL of patientsin the area of disease prevention.
 We will bolster our domestic foundation, centered on our relationship with
BIKEN.
 We will take steps to contribute to maximizing value as the top domestic
brand, such as offering an influenza vaccine, a Japanese encephalitis
vaccine, and a combination vaccine for four diseases.
 Launch of Tetra vaccine, Tetrabik We will independently in-license competitive products and technologies,
develop and provide new products, with consideration for global use
Build a system that is suitable for production and development incooperation with Medicago
Consider cooperative activities with a view to global development
47

Strengthening and Enhancing
the Generic Business
Generics Business Policy
Provide “Reliable Generics” that leverage the strengths of the Group’s
organizational foundation (new drugs, specialized areas)<Environmental Changes>
 Market growth due to progress in measures to promote the use of generics
 Intensifying competition due to new market entrants and bolstered operations

 Response to major drugs coming off patent Strengthen the earning power using the group marketing foundation at a
maximum (not only Tanabe Seiyaku Hanbai but also MTPC and Yoshitomiyakuhin) Targeting the FY2015 sales objective of ¥50.0 billion, we will further enhance ourpresence, with consideration for strategic tie-ups.
48

Bolstering of Major Base Function
Medium-Term Management Plan 11-15
Bolstering of Major Base Function

Research
facilities

Head office,etc.

■ Research Headquarters: Completed transfer/consolidationof research functions at Yokohama and Toda.
■ CMC Research Center: Bolstered CMC research facilities at
Kashima.
■ Completed reorganization / relocation of Tokyo head officebuilding (Nihonbashi, Sanbancho)■ Construction / relocation of Osaka head office building■ Constructed Kashima office building49

Bolstering Production Bases
New drug production building
at Tianjin Tanabe

New drug production building
at Yoshitomi Plant (Fukuoka Prefecture)(Start construction in 2014, finish in 2016)(Start construction in 2013, finish in 2015)(Tianjin, China)

Bolster production capacity toaccommodate demand growth inChina and Asia.

Enhance new drug supply system andachieve optimal production system

New drug production building
at P.T. Tanabe Indonesia

New drug production building
at Onoda Plant (Yamaguchi Prefecture)(Start construction in 2013, finish in 2014)(Start construction in 2014, finish in 2016)(Bandung, Indonesia)

During the period covered by the current medium-term management plan, we will invest a total of
about ¥20.0 billion to build new plants to global standards at production bases in Japan and overseas.
In addition, we will strengthen the clinical drug facility function.
50

Other Initiatives
Contributing to KAITEKI Society by orchestrating

Page.51

51
51

Contributing to KAITEKI Society
by orchestrating

OTC business
Health Ahead sick
MCHC groupcompanies

Academia

Ethicalpharmaceuticalbusiness
New
GE
drugs
businessbusiness
Treatment

Cure, recovery

Ventures

Contributing to KAITEKI society

Vaccinebusiness

Pharmaceutical/healthcare companies
52

Toward Achievement of FY2015 Targets

Page.5353
53

Growth Drivers in the Future
Creating a sustained growth by increasing
revenues from home and abroad

Launch of the promising pipeline
MT-1303
MT-3995

MP-214 MT-4666
MT-9938

Overseas: Expansion of royalty income
Gilenya TA-7284
Japan: Nurturing of new products andpriority products

Remicade, Talion,
Simponi, Lexapro, Telavic, Imusera, Tenelia, Tetrabik, TA-7284（under development）

Medium-Term Management Plan 11-15 (-FY2015)

FY201654

Toward Achievement of FY2015 Targets
JPY b
JPY b

100

Net Sales

100

Operating Income
500

69

500.0
500

70

80

60

450

429.0
425.0
400

100

40

407.1
20

Medium-Term Management Plan 11-15
0350
FY2011FY2012E

FY2013

FY2014FY201555

Becoming a “Company that Can Continue to Create New Value”

56

Cautionary Statement
The statements contained in this presentation is based on a numberof assumptions and belief in light of the information currently available
to management of the company and is subject to significant
risks and uncertainties.

57